Current Report · Items 8.01, 9.01 · 8-K/A
VSee Health, Inc.
VSEENASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. As previously reported, on September 2, 2025, the Company received a notification letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”) because the Company’s stockholders’ equity had fallen below the $2,…
Filed Dec 11, 2025Accepted Dec 11, 2025, 10:17 AM ESTCIK 1864531Accession 0001185185-25-002019
Company context
VSee Health (NASDAQ:VSEE) is a telehealth technology and services company delivering high-acuity virtual care solutions through its scalable, API-driven platform. The Company’s offerings integrate secure video, device data, and EHR connectivity to power hospital systems, health networks, and employers across the United States. For more information, please visit vseehealth.com.
Current securities
Historical securities (3)
Disclosure sections
Items 8.01, 9.01Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
As previously reported, on September 2, 2025,
the Company received a notification letter (the “Letter”) from the Listing Qualifications Department (the “Staff”)
of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1)
(the “Equity Rule”) because the Company’s stockholders’ equity had fallen below the $2,500,000 required minimum
for continued listing. The Company’s stockholders’ deficit was $18,488 as of December 31, 2024, as reported in the Company’s
Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The Company filed an appeal of the determination to delist
the Company’s securities with the Nasdaq Hearings Panel (the “Panel”) and a hearing before the Panel was held
on September 9, 2025 (the “Hearing”). Based on the information presented by the Company at the Hearing, the Panel determined
to grant the Company’s request for an exception to complete its compliance plan.
The Staff subsequently notified the Company that
the Panel, among other things, decided to grant the Company’s request for continued listing on the Nasdaq Capital Market subject
to the Company demonstrating, on or before December 1, 2025, compliance with the Equity Rule by filing public disclosure describing the
transactions undertaken by the Company to achieve compliance with the Equity Rule and demonstrate long-term compliance with the Equity
Rule, and by providing an indication of its equity following those transactions. The Panel noted that the Company may do so by including
in the public disclosure a balance sheet not older than 60 days with pro forma adjustments for any significant transactions or events.
The Company believes that it has demonstrated
compliance with the Equity Rule on a pro forma basis following closing of the following the exercise of certain outstanding warrants,
the conversion into common stock of multiple outstanding convertible notes and preferred shares, and the exchange of certain outstanding
payables of the Company into common stock and preferred shares (collectively, the “Transactions”):
A pro forma balance sheet, assuming
the Transactions closed as of December 1, 2025, shows total stockholders’ equity of $9.5 million, reflecting compliance with the Equity Rule,
and is filed as Exhibit 99.1 to this Current Report on Form 8-K.
Filed exhibits (1)
EX-99.1 (by filename) vseeex99-1.htmEX-99.1
2
vseeex99-1.htm
EXHIBIT 99.1
Exhibit 99.1
September 30, Convertible Debt Transactions Warrant Conversion Transaction Pipe Investment Transaction Pro Forma December 31,
December 1,
2025 (A) (B) (C) 20…
Open exhibit ↗